GLP-1 Receptor Agonists Linked to Lower Mortality for Patients With Brain Metastases, T2DM
FRIDAY, March 13, 2026 — For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research…
Wegovy users may have 5 times risk of vision loss than those on Ozempic
Berberine as a natural Ozempic? An analysis of a popular myth
In recent years, berberine has increasingly appeared in the public sphere as a “natural way” to improve metabolism. In social media, it is sometimes compared to incretin drugs and even referred to as “plant-based Ozempic.” Such comparisons suggest a simple mechanism of action and predictable effects.
Persistence With GLP-1 Receptor Agonist Therapy Remains Low Among Those With Overweight, Obesity
THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online…
Impurity in Some Compounded Tirzepatide ‘Potentially Dangerous,’ Eli Lilly Warns
(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…
Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy
THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…
Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide
Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.
Compounders prescribing GLP-1s put pricing pressure on Novo, Lilly
Hims won — for now.
Since 2022, telehealth companies and compounding pharmacies have brought a new type of competition for drugmakers. Pharma giants, long protected by patents and market exclusivity, suddenly found themselves undercut on price …
Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Compounded forms of the molecule behind Eli Lilly’s metabolic blockbusters Mounjaro and Zepbound that have vitamin B12 added to them may be unsafe, Lilly said Thursday.
Lilly and its fellow GLP-1-based drugmaker Novo Nordisk have …
Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.What’s more, those patients who do swap GLP-1 drugs are mor…